Clinical Trial

A Study of JNJ-1761981 in Participants With Solid Tumors

Name: A Study of JNJ-1761981 in Participants With Solid Tumors — clinical trial record (NCT07525141)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-15

Trial Details

NCT Number	NCT07525141
Lead Sponsor	Johnson & Johnson Enterprise Innovation Inc.
Conditions	Neoplasms
Enrollment	66 participants
Start Date	2026-05-18
Primary Completion	2028-01-12 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-06